Core Insights - TuHURA Biosciences, Inc. has achieved a milestone in its clinical trial for REM-001, demonstrating safety and signs of clinical efficacy in ten metastatic cutaneous breast cancer patients after eight weeks of follow-up [1][2] Group 1: Company Overview - TuHURA Biosciences, Inc. is a Phase 3 immuno-oncology company focused on developing novel therapeutics to address resistance to cancer immunotherapy, a significant challenge in cancer treatment [3] - The company's lead product, IFx-2.0, aims to overcome primary resistance to checkpoint inhibitors and is currently in a Phase 3 trial as an adjunctive therapy to Keytruda® for advanced or metastatic Merkel Cell Carcinoma [4] Group 2: Recent Developments - Following the successful completion of the REM-001 trial, TuHURA will release an aggregate of 1,539,958 shares of common stock to legacy Kintara Therapeutics stockholders as per the Contingent Value Rights Agreement [2] - TuHURA has also acquired TBS-2025 through its merger with Kineta Inc., which is moving into Phase 2 development for mutNPM1 r/r AML [5]